Reuters logo
2 个月前
BRIEF-Corbus announces last subject enrolled in Phase 2 study of anabasum
2017年5月11日 / 下午12点33分 / 2 个月前

BRIEF-Corbus announces last subject enrolled in Phase 2 study of anabasum

1 分钟阅读

May 11 (Reuters) - Corbus Pharmaceuticals Holdings Inc

* Corbus pharmaceuticals announces last subject enrolled in phase 2 study of anabasum for the treatment of skin-predominant dermatomyositis

* Corbus pharmaceuticals holdings inc- company expects topline results from study to be available in q4 of 2017. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below